

SAFETY DATA SHEET



PLATIN 4545-30 - All variants

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : PLATIN 4545-30 - All variants

1.2 Relevant identified uses of the substance or mixture and uses advised against

Product use : Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person responsible for this SDS : Prod-safe@teknos.com

National contact

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

1.4 Emergency telephone number

National advisory body/Poison Centre

Telephone number : Emergency medical information: (seven days) contact National Poisons Information Centre, Beaumont Hospital, Dublin 9 DOV2NO, Ireland.
Members of the public Number (8 am-10 pm): +353 (0)1 809 2166
Healthcare professional telephone Number (24hrs): +353 (0)1 809 2566

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Signal word : No signal word.

Hazard statements : No known significant effects or critical hazards.

Precautionary statements

Prevention : Not applicable.

Response : Not applicable.

Storage : Not applicable.

Disposal : Not applicable.

Supplemental label elements : Contains 1,2-benzisothiazol-3(2H)-one and reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1). May produce an allergic reaction.
Safety data sheet available on request.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles :

Date of issue/Date of revision

: 24/04/2025

Date of previous issue

: 03/04/2024

Version : 1.01 1/17

PLATIN 4545-30 - All variants

Label No :38817

SECTION 2: Hazards identification

2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII : This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Other hazards which do not result in classification : None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures : Mixture

Product/ingredient name	Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Type
Propylene glycol	REACH #: 01-2119456809-23 EC: 200-338-0 CAS: 57-55-6	≤10	Not classified.	-	[2]
2-(2-butoxyethoxy)ethanol	REACH #: 01-2119475104-44 EC: 203-961-6 CAS: 112-34-5 Index: 603-096-00-8	≤3	Eye Irrit. 2, H319	-	[1] [2]
2-Butoxyethanol	REACH #: 01-2119475108-36 EC: 203-905-0 CAS: 111-76-2 Index: 603-014-00-0	≤3	Acute Tox. 4, H302 Acute Tox. 3, H331 Skin Irrit. 2, H315 Eye Irrit. 2, H319	ATE [Oral] = 1200 mg/kg ATE [Inhalation (vapours)] = 3 mg/l	[1] [2]
1,2-benzisothiazol-3(2H)-one	EC: 220-120-9 CAS: 2634-33-5 Index: 613-088-00-6	<0.036	Acute Tox. 4, H302 Acute Tox. 2, H330 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410	ATE [Oral] = 450 mg/kg ATE [Inhalation (dusts and mists)] = 0.21 mg/l Skin Sens. 1, H317: C ≥ 0.036% M [Acute] = 1 M [Chronic] = 1	[1]
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	EC: 911-418-6 CAS: 55965-84-9 Index: 613-167-00-5	<0.0015	Acute Tox. 3, H301 Acute Tox. 2, H310 Acute Tox. 2, H330 Skin Corr. 1C, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071	ATE [Oral] = 53 mg/kg ATE [Dermal] = 50 mg/kg ATE [Inhalation (vapours)] = 0.5 mg/l Skin Corr. 1C, H314: C ≥ 0.6% Eye Dam. 1, H318: C ≥ 0.6% Eye Irrit. 2, H319: 0.06% ≤ C < 0.6% Skin Sens. 1, H317: C ≥ 0.0015% M [Acute] = 100 M [Chronic] = 100	[1]
			See Section 16 for the full text of the H statements declared above.		

SECTION 3: Composition/information on ingredients

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
- Ingestion** : Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training.

4.2 Most important symptoms and effects, both acute and delayed

Over-exposure signs/symptoms

- Eye contact** : No specific data.
- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

- Notes to physician** : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Specific treatments** : No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : None known.

5.2 Special hazards arising from the substance or mixture

- Hazards from the substance or mixture** : In a fire or if heated, a pressure increase will occur and the container may burst.
- Hazardous combustion products** : Decomposition products may include the following materials:
carbon dioxide
carbon monoxide
nitrogen oxides

5.3 Advice for firefighters

SECTION 5: Firefighting measures

- Special protective actions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
- For emergency responders** : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions

- : Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and material for containment and cleaning up

- Small spill** :  Stop leak if without risk. Move containers from spill area. Absorb with an inert material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
- Large spill** :  Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contain and collect spillage with non-combustible, absorbent material e. g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.

6.4 Reference to other sections

- : See Section 1 for emergency contact information.
See Section 8 for information on appropriate personal protective equipment.
See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

- Protective measures** : Put on appropriate personal protective equipment (see Section 8).
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

 Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

- Recommendations** : Not available.

SECTION 7: Handling and storage

Industrial sector specific solutions : Not available.

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values
Propylene glycol	NAOSH (Ireland, 4/2024) Notes: Advisory Occupational Exposure Limit Values (OELVs) OELV 8 hours: 10 mg/m ³ . Form: particulate. OELV 8 hours: 470 mg/m ³ . Form: vapour and particulates. OELV 8 hours: 150 ppm. Form: vapour and particulates.
2-(2-butoxyethoxy)ethanol	NAOSH (Ireland, 4/2024) Notes: EU derived Occupational Exposure Limit Values OELV 8 hours: 10 ppm. OELV 15 minutes: 101.2 mg/m ³ . OELV 8 hours: 67.5 mg/m ³ . OELV 15 minutes: 15 ppm.
2-Butoxyethanol	NAOSH (Ireland, 4/2024) Absorbed through skin. Notes: EU derived Occupational Exposure Limit Values OELV 8 hours: 20 ppm. OELV 8 hours: 98 mg/m ³ . OELV 15 minutes: 50 ppm. OELV 15 minutes: 246 mg/m ³ .

Biological exposure indices

Product/ingredient name	Exposure indices
2-Butoxyethanol	NAOSH (Ireland, 1/2011) BMGV: 200 mg/g creatinine, BAA [in urine]. Sampling time: end of shift - As soon as possible after exposure ceases.

Recommended monitoring procedures : Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

Product/ingredient name	Result
2-(2-butoxyethoxy)ethanol	DNEL - General population - Long term - Oral 6.25 mg/kg bw/day <u>Effects</u> : Systemic DNEL - Workers - Long term - Inhalation 67.5 mg/m ³ <u>Effects</u> : Local DNEL - Workers - Short term - Inhalation 101.2 mg/m ³ <u>Effects</u> : Local
2-Butoxyethanol	DNEL - General population - Long term - Oral 6.3 mg/kg bw/day <u>Effects</u> : Systemic

SECTION 8: Exposure controls/personal protection

DNEL - General population - Short term - Oral

26.7 mg/kg bw/day

Effects: Systemic

DNEL - General population - Long term - Inhalation

59 mg/m³

Effects: Systemic

DNEL - Workers - Long term - Inhalation

98 mg/m³

Effects: Systemic

DNEL - General population - Short term - Inhalation

147 mg/m³

Effects: Local

DNEL - Workers - Short term - Inhalation

246 mg/m³

Effects: Local

DNEL - General population - Short term - Inhalation

426 mg/m³

Effects: Systemic

DNEL - Workers - Short term - Inhalation

1091 mg/m³

Effects: Systemic

1,2-benzisothiazol-3(2H)-one

DNEL - General population - Long term - Dermal

0.345 mg/kg bw/day

Effects: Systemic

DNEL - Workers - Long term - Dermal

0.966 mg/kg bw/day

Effects: Systemic

DNEL - General population - Long term - Inhalation

1.2 mg/m³

Effects: Systemic

DNEL - Workers - Long term - Inhalation

6.81 mg/m³

Effects: Systemic

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)

DNEL - General population - Long term - Inhalation

0.02 mg/m³

Effects: Local

DNEL - Workers - Long term - Inhalation

0.02 mg/m³

Effects: Local

DNEL - General population - Short term - Inhalation

0.04 mg/m³

Effects: Local

DNEL - Workers - Short term - Inhalation

0.04 mg/m³

Effects: Local

DNEL - General population - Long term - Oral

0.09 mg/kg bw/day

Effects: Systemic

SECTION 8: Exposure controls/personal protection

DNEL - General population - Short term - Oral

0.11 mg/kg bw/day

Effects: Systemic

PNECs

Not available.

8.2 Exposure controls

Appropriate engineering controls : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Individual protection measures

Hygiene measures : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Recommendations : Wear suitable gloves tested to EN374.

> 8 hours (breakthrough time): Nitrile gloves. thickness > 0.3 mm

Not recommended polyvinyl alcohol (PVA) gloves

Body protection : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Filter type (spray application): A P

Environmental exposure controls : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

Appearance

Physical state : Liquid.

Colour : Various

Odour : Slight

Odour threshold : Not available.

Melting point/freezing point : Not available.

SECTION 9: Physical and chemical properties

Initial boiling point and boiling range :

Ingredient name	°C	°F	Method
water	100	212	
2-Butoxyethanol	171 to 171.5	339.8 to 340.7	IP 123-93

Flammability : Not available.

Lower and upper explosion limit : Lower: 0.8% (2-(2-butoxyethoxy)ethanol)
Upper: 12.6% (propane-1,2-diol)

Flash point : Closed cup: >100°C (>212°F)

Auto-ignition temperature :

Ingredient name	°C	°F	Method
2-(2-butoxyethoxy)ethanol	210	410	DIN 51794
2-Butoxyethanol	230	446	DIN 51794

Decomposition temperature : Not available.

pH : 7 to 9

Viscosity : Not available.

Solubility(ies) :

Not available.

Solubility in water : Not available.

Partition coefficient: n-octanol/ water : Not applicable.

Vapour pressure :

Ingredient name	Vapour Pressure at 20°C			Vapour pressure at 50°C		
	mm Hg	kPa	Method	mm Hg	kPa	Method
water	17.5	2.3				
2-Butoxyethanol	0.75006	0.1				

Relative density : Not available.

Density : 1.1 g/cm³

Vapour density : Not available.

Particle characteristics

Median particle size : Not applicable.

9.2 Other information

9.2.1 Information with regard to physical hazard classes

Explosive properties : Not available.

Oxidising properties : Not available.

9.2.2 Other safety characteristics

Not applicable.

SECTION 10: Stability and reactivity

10.1 Reactivity : No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability : The product is stable.

10.3 Possibility of hazardous reactions : Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid : No specific data.

Date of issue/Date of revision : 24/04/2025 **Date of previous issue** : 03/04/2024

Version : 1.01 8/17

PLATIN 4545-30 - All variants

Label No :38817

SECTION 10: Stability and reactivity

10.5 Incompatible materials : No specific data.

10.6 Hazardous decomposition products : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute toxicity

Product/ingredient name	Result
2-(2-butoxyethoxy)ethanol	Rabbit - Dermal - LD50 2700 mg/kg Rat - Oral - LD50 4500 mg/kg <u>Toxic effects:</u> Behavioral - Tetany Lung, Thorax, or Respiration - Dyspnea Liver - Other changes
1,2-benzisothiazol-3(2H)-one	Rat - Oral - LD50 1020 mg/kg
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	Rat - Oral - LD50 53 mg/kg <u>Toxic effects:</u> Behavioral - Somnolence (general depressed activity) Behavioral - Ataxia Lung, Thorax, or Respiration - Respiratory depression

Conclusion/Summary [Product] : Not available.

Acute toxicity estimates

Product/ingredient name	Oral (mg/kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
PLATIN 4545-30	60000.0	N/A	164759.0	150.0	N/A
2-(2-butoxyethoxy)ethanol	4500	2700	N/A	N/A	N/A
2-Butoxyethanol	1200	N/A	N/A	3	N/A
1,2-benzisothiazol-3(2H)-one	450	N/A	N/A	N/A	0.21
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	53	50	N/A	0.5	N/A

Skin corrosion/irritation

Product/ingredient name	Result
2-Butoxyethanol	Rabbit - Skin - Mild irritant <u>Amount/concentration applied:</u> 500 mg
1,2-benzisothiazol-3(2H)-one	Human - Skin - Mild irritant <u>Duration of treatment/exposure:</u> 48 hours <u>Amount/concentration applied:</u> 5 %
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	Human - Skin - Severe irritant <u>Amount/concentration applied:</u> 0.01 %

Conclusion/Summary [Product] : Not available.

Serious eye damage/eye irritation

Product/ingredient name	Result
-------------------------	--------

SECTION 11: Toxicological information

 (2-butoxyethoxy)ethanol

Rabbit - Eyes - Moderate irritant

Duration of treatment/exposure: 24 hours

Amount/concentration applied: 20 mg

Rabbit - Eyes - Severe irritant

Amount/concentration applied: 20 mg

2-Butoxyethanol

Rabbit - Eyes - Moderate irritant

Duration of treatment/exposure: 24 hours

Amount/concentration applied: 100 mg

Rabbit - Eyes - Severe irritant

Amount/concentration applied: 100 mg

Conclusion/Summary [Product] : Not available.

Respiratory corrosion/irritation

Not available.

Conclusion/Summary [Product] : Not available.

Respiratory or skin sensitization

Not available.

Skin

Conclusion/Summary [Product] : Not available.

Respiratory

Conclusion/Summary [Product] : Not available.

Germ cell mutagenicity

Not available.

Conclusion/Summary [Product] :  Not available.

Carcinogenicity

Not available.

Conclusion/Summary [Product] :  Not available.

Reproductive toxicity

Not available.

Conclusion/Summary [Product] :  Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on likely routes of exposure

Date of issue/Date of revision

: 24/04/2025

Date of previous issue

: 03/04/2024

Version : 1.01 10/17

 LATIN 4545-30 - All variants

Label No :38817

SECTION 11: Toxicological information

Not available.

Potential acute health effects

Eye contact	: No known significant effects or critical hazards.
Inhalation	: No known significant effects or critical hazards.
Skin contact	: No known significant effects or critical hazards.
Ingestion	: No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact	: No specific data.
Inhalation	: No specific data.
Skin contact	: No specific data.
Ingestion	: No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Short term exposure

Potential immediate effects	: Not available.
Potential delayed effects	: Not available.

Long term exposure

Potential immediate effects	: Not available.
Potential delayed effects	: Not available.

Potential chronic health effects

Not available.

Conclusion/Summary [Product]	: Not available.
General	: No known significant effects or critical hazards.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Not available.

Conclusion/Summary [Product]	: The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.
-------------------------------------	--

11.2.2 Other information

Not available.

SECTION 12: Ecological information

12.1 Toxicity

Product/ingredient name

2-(2-butoxyethoxy)ethanol

2-Butoxyethanol

Result

Acute - LC50 - Fresh water

Fish - Bluegill - *Lepomis macrochirus*

Size: 33 to 75 mm

1300000 µg/l [96 hours]

Effect: Mortality

Acute - LC50 - Marine water

Fish - Inland silverside - *Menidia beryllina*

Size: 40 to 100 mm

1250000 µg/l [96 hours]

Effect: Mortality

Acute - LC50 - Marine water

Crustaceans - Common shrimp, sand shrimp - *Crangon crangon*

SECTION 12: Ecological information

800000 µg/l [48 hours]

Effect: Mortality

1,2-benzisothiazol-3(2H)-one

Acute - LC50 - Fresh water

OECD [Fish, Acute Toxicity Test]

Fish - Trout - *Onorhynchus Mykiss*

1.9 mg/l [96 hours]

Acute - EC50

OECD 202 [Daphnia sp. Acute Immobilization Test and Reproduction Test]

Daphnia - Daphnia - *Daphnia Magna*

3.7 mg/l [48 hours]

Acute - EC50 - Marine water

OECD 201 [Alga, Growth Inhibition Test]

Algae - Algae - *Skeletonema Costatum*

0.36 mg/l [72 hours]

Acute - NOEC - Marine water

OECD 201 [Alga, Growth Inhibition Test]

Algae - Algae - *Skeletonema Costatum*

0.15 mg/l [72 hours]

Conclusion/Summary [Product] : Not available.

12.2 Persistence and degradability

Product/ingredient name

1,2-benzisothiazol-3(2H)-one

Result

EU

24% [28 days]

Conclusion/Summary [Product] : Not available.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
1,2-benzisothiazol-3(2H)-one	-	-	Inherent

12.3 Bioaccumulative potential

Product/ingredient name	LogP _{ow}	BCF	Potential
2-(2-butoxyethoxy)ethanol	1	-	Low
2-Butoxyethanol	0.81	-	Low
1,2-benzisothiazol-3(2H)-one	-	3.2	Low

12.4 Mobility in soil

Soil/water partition coefficient

Product/ingredient name	logK _{oc}	K _{oc}
2-(2-butoxyethoxy)ethanol	1.56	36.5981
2-Butoxyethanol	1.83	67.3685
1,2-benzisothiazol-3(2H)-one	1.86	73.142

Results of PMT and vPvM assessment

Product/ingredient name	PMT	P	M	T	vPvM	vP	vM
2-(2-butoxyethoxy)ethanol	No	No	No	No	No	No	No
2-Butoxyethanol	No	No	No	No	No	No	No
1,2-benzisothiazol-3(2H)-one	No	No	No	No	No	No	No
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	No	No	No	No	No	No	No

Date of issue/Date of revision

: 24/04/2025

Date of previous issue

: 03/04/2024

Version : 1.01 12/17

PLATIN 4545-30 - All variants

Label No : 38817

SECTION 12: Ecological information

Mobility : Not available.

Conclusion/Summary : The product does not meet the criteria to be considered as a PMT or vPvM.

12.5 Results of PBT and vPvB assessment

Regulation (EC) No. 1907/2006 [REACH]

Product/ingredient name	PBT	P	B	T	vPvB	vP	vB
2-(2-butoxyethoxy)ethanol	No	No	No	No	No	No	No
2-Butoxyethanol	No	No	No	No	No	No	No
1,2-benzisothiazol-3(2H)-one	No	No	No	No	No	No	No
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	No	No	No	No	No	No	No

Regulation (EC) No. 1272/2008 [CLP]

Product/ingredient name	PBT	P	B	T	vPvB	vP	vB
2-(2-butoxyethoxy)ethanol	No	No	No	No	No	No	No
2-Butoxyethanol	No	No	No	No	No	No	No
1,2-benzisothiazol-3(2H)-one	No	No	No	No	No	No	No
reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)	No	No	No	No	No	No	No

Conclusion/Summary : The product does not meet the criteria to be considered as a PBT or vPvB.

Regulation (EC) No. 1272/2008 [CLP]

12.6 Endocrine disrupting properties

Not available.

Conclusion/Summary [Product] : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

European waste catalogue (EWC) : 08.01.19

Packaging

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

SECTION 13: Disposal considerations

Special precautions : This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	ADN	IMDG	IATA
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-	-
14.3 Transport hazard class(es)	-	-	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No.	No.	No.	No.

14.6 Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Maritime transport in bulk according to IMO instruments : Not relevant/applicable due to nature of the product.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Product/ingredient name	%	Designation [Usage]
2-(2-butoxyethoxy)ethanol	≤3	55 [Consumer paint]

Labelling :

Other EU regulations

Industrial emissions (integrated pollution prevention and control) - Air : Not listed

Industrial emissions (integrated pollution prevention and control) - Water : Not listed

Explosive precursors : Not applicable.

Ozone depleting substances (EU 2024/590)

SECTION 15: Regulatory information

Not listed.

[Prior Informed Consent \(PIC\) \(649/2012/EU\)](#)

Not listed.

[Persistent Organic Pollutants](#)

Not listed.

[Seveso Directive](#)

This product is not controlled under the Seveso Directive.

[International regulations](#)

[Chemical Weapon Convention List Schedules I, II & III Chemicals](#)

Not listed.

[Montreal Protocol](#)

Not listed.

[Stockholm Convention on Persistent Organic Pollutants](#)

Not listed.

[Rotterdam Convention on Prior Informed Consent \(PIC\)](#)

Not listed.

[UNECE Aarhus Protocol on POPs and Heavy Metals](#)

Not listed.

15.2 Chemical safety assessment

: This product contains substances for which Chemical Safety Assessments are still required.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms

: ATE = Acute Toxicity Estimate
CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]
DMEL = Derived Minimal Effect Level
DNEL = Derived No Effect Level
EUH statement = CLP-specific Hazard statement
N/A = Not available
PBT = Persistent, Bioaccumulative and Toxic
PNEC = Predicted No Effect Concentration
RRN = REACH Registration Number
SGG = Segregation Group
vPvB = Very Persistent and Very Bioaccumulative

[Procedure used to derive the classification according to Regulation \(EC\) No. 1272/2008 \[CLP/GHS\]](#)

Not classified.

[Full text of abbreviated H statements](#)

H301	Toxic if swallowed.
H302	Harmful if swallowed.
H310	Fatal in contact with skin.
H314	Causes severe skin burns and eye damage.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H319	Causes serious eye irritation.
H330	Fatal if inhaled.
H331	Toxic if inhaled.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
EUH071	Corrosive to the respiratory tract.

[Full text of classifications \[CLP/GHS\]](#)

Date of issue/Date of revision

: 24/04/2025

Date of previous issue

: 03/04/2024

Version : 1.01 15/17

PLATIN 4545-30 - All variants

Label No : 38817

SECTION 16: Other information

 Acute Tox. 2	ACUTE TOXICITY - Category 2
Acute Tox. 3	ACUTE TOXICITY - Category 3
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Acute 1	SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1
Eye Dam. 1	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Skin Corr. 1C	SKIN CORROSION/IRRITATION - Category 1C
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1A	SKIN SENSITISATION - Category 1A

Date of issue/ Date of revision : 24/04/2025

Date of previous issue : 03/04/2024

Version : 1.01

 LATIN 4545-30

 variants

Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

